SSelectStock
Sign in

MANKINDMankind Pharma Limited

Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-07-20 (delayed ~30 min in market hours)

2,565.80
3.28%
73Strong

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)1,04,533.40
P/E54.56
P/B6.41
PEG1.72
ROE %12.45
ROCE %12.50
Debt / Equity0.38
EPS46.39
Revenue Growth %11.80
Profit Growth %31.70
Dividend Yield %0.04
Promoter Holding %75.40
FII Holding %20.01
DII Holding %
Beta0.45

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

Pullback to 21-EMALONG78%2,565.802,469.502,700.301.40
BUYConviction 83%

Why buy

  • Profit growth: 31.7% YoY
  • Debt/Equity: 0.38
  • Promoter holding: 75.4%
  • RSI: 60
  • Price vs EMA21: above
  • Price vs SMA50: above
  • Pullback to 21-EMA signal (setup quality 78%)

Bull case

  • Profit growth: 31.7% YoY
  • Debt/Equity: 0.38
  • Promoter holding: 75.4%
  • RSI: 60

Bear case

  • Dividend yield: 0.04%
  • MACD: bearish
  • Volume trend: 0.8x baseline

Key risks

  • Dividend yield: 0.04%
  • MACD: bearish

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹2,565.80
Stop Loss
₹2,432.43
risk 5.2%
Target 1 (1.5R)
₹2,765.86
+7.8%
Target 2 (3R)
₹2,965.91
+15.6%
Support (20d)
₹2,457.00
Resistance (52w)
₹2,715.43
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹133.37/share
ATR (volatility)
₹67.67
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹67.67). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental
64
Technical
76
Momentum
79
Risk (safety)
74

Peers — Pharma

PGHL 0.78%
84
AJANTPHARM 1.45%
82
HESTERBIO 3.09%
81
LUPIN 1.44%
80
SUNPHARMA 1.23%
80
CORONA 0.78%
79

About

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory, and other diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural and pet food products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Telmikind-Am, Gudcef, Glimestar-M, Candi Force, Nurokind-Gold, Telmikind-H, Telmikind, Nurokind-Lc, Nurokind Plus-Rf, Vomikind, Cefakind, Glizid-M, Monticope, and Gudcef-Cv brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.